HALO

Halozyme Therapeutics licenses proprietary drug delivery technology to major pharmaceutical companies, allowing complex intravenous treatments to be administered as quick injections. This asset-light model generates significant recurring royalty and milestone revenues without the heavy research and development risks typically associated with traditional biotech firms. I have synthesized my analysis of its core fundamentals, live market action, and peer metrics to provide a comprehensive thesis. What specific areas can I detail for you?